Literature DB >> 12399972

Identification of precursors of leukemic dendritic cells differentiated from patients with acute myeloid leukemia.

M Mohty1, D Isnardon, D Blaise, M-J Mozziconacci, M Lafage-Pochitaloff, F Brière, J-A Gastaut, D Olive, B Gaugler.   

Abstract

Dendritic cells (DC) can facilitate immune responses that might help in the induction of effective antitumor T cell responses. We reported previously that leukemic blasts from selected patients with acute myeloid leukemia (AML) were able to differentiate in vitro into cells with mature DC features. However, despite the use of a wide variety of cytokine combinations, leukemic DC could not be obtained from all AML patients. In this study, we investigated in a wide range of AML patients (n = 30), the nature and functional characteristics of the blast compartment that can be induced to acquire DC features in vitro. Our results demonstrate that leukemic DC generated in the presence of GM-CSF, IL-4 and matured with CD40L, are composed of two major subsets: DC derived from CD14(+) leukemic cells and leukemic DC derived from in vivo expanded circulating blood myeloid DC (MDC). Leukemic DC of both subsets exhibited DC morphology, had a phenotype of mature DC, and could induce a potent proliferative response of naive CD4(+) T cells. Moreover, both subsets produced large amounts of IL-12p70 and leukemic CD14(+)-derived DC could induce a potent Th1 response. These results can be considered as a prerequisite before the design of vaccine immunotherapy protocols for the adjuvant treatment of AML patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12399972     DOI: 10.1038/sj.leu.2402706

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  4 in total

Review 1.  Dendritic Cells of Leukemic Origin: Specialized Antigen-Presenting Cells as Potential Treatment Tools for Patients with Myeloid Leukemia.

Authors:  Daniel Christoph Amberger; Helga Maria Schmetzer
Journal:  Transfus Med Hemother       Date:  2020-11-05       Impact factor: 3.747

2.  Serum-resistant CpG-STAT3 decoy for targeting survival and immune checkpoint signaling in acute myeloid leukemia.

Authors:  Qifang Zhang; Dewan Md Sakib Hossain; Priyanka Duttagupta; Dayson Moreira; Xingli Zhao; Haejung Won; Ralf Buettner; Sergey Nechaev; Marcin Majka; Bin Zhang; Qi Cai; Piotr Swiderski; Ya-Huei Kuo; Stephen Forman; Guido Marcucci; Marcin Kortylewski
Journal:  Blood       Date:  2016-01-21       Impact factor: 22.113

3.  Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity.

Authors:  Dewan Md Sakib Hossain; Cedric Dos Santos; Qifang Zhang; Anna Kozlowska; Hongjun Liu; Chan Gao; Dayson Moreira; Piotr Swiderski; Agnieszka Jozwiak; Justin Kline; Stephen Forman; Ravi Bhatia; Ya-Huei Kuo; Marcin Kortylewski
Journal:  Blood       Date:  2013-10-29       Impact factor: 22.113

4.  A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission.

Authors:  Jennifer L Hsu; Christian E Bryant; Michael S Papadimitrious; Benjamin Kong; Robin E Gasiorowski; Daniel Orellana; Helen M McGuire; Barbara Fazekas de St Groth; Douglas E Joshua; P Joy Ho; Stephen Larsen; Harry J Iland; John Gibson; Georgina J Clark; Phillip D Fromm; Derek Nj Hart
Journal:  Oncoimmunology       Date:  2018-01-25       Impact factor: 8.110

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.